StockNews.AI
EHC
StockNews.AI
23 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Encompass Health Corporation - EHC

1. Pomerantz LLP investigates potential securities fraud by Encompass Health. Claims involve unsafe practices leading to patient fatalities. 2. The New York Times reports Encompass hospitals perform below average on safety measures. 3. Encompass-owned rehabs have high rates of preventable readmissions, affecting stock prices. 4. Encompass's stock dropped 10.35% after negative report on July 15, 2025. 5. Class action investigation raises concerns over Encompass's corporate governance.

5m saved
Insight
Article

FAQ

Why Bearish?

The investigation and negative media coverage have directly led to stock price decline. Similar patterns have been observed in past cases where companies faced allegations resulting in significant drops.

How important is it?

The potential for legal ramifications and negative health performance to influence investor sentiment significantly impacts stock valuation.

Why Short Term?

Immediate impacts due to ongoing investigations; however, long-term effects depend on resolution outcomes and public sentiment.

Related Companies

HCAUHSCYH
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE: EHC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action]  On July 15, 2025, citing federal data and inspection reports, The New York Times published an article alleging that for-profit hospitals run by Encompass perform below average on key safety measures. The article reported that "Encompass owns many of the rehabs with worse rates of potentially preventable, unplanned readmissions to general hospitals" including 34 facilities which "Medicare rated as having statistically significantly worse rates of potentially preventable readmissions." The article further described a number of "alarming mistakes" leading to fatalities of patients in the care of Encompass-owned facilities.  Following publication of the article, Encompass's stock price fell $12.39 per share, or 10.35%, to close at $107.28 per share on July 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News